Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2010
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Radius Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, EffRx will grant Radius an exclusive, royalty bearing license to Binosto (alendronate sodium), an effervescent tablet for oral solution indicated for osteoporosis in postmenopausal women and to increase bone mass in men with osteopor...
Product Name : Binosto
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 19, 2023
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Radius Health
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Approved FDF
Sponsor : Abiogen Pharma S.p.A
Deal Size : Undisclosed
Deal Type : Acquisition
Abiogen Pharma Completes the Acquisition of EffRx Pharmaceuticals
Details : Through the acquisition, Abiogen gets Effrx's Binosto (alendronate sodium), an effervescent tablet for the treatment of osteoporosis. It will allow Abiogen to continue developing on Effrx's bisphosphonates family of molecules that in the area of os...
Product Name : Binosto
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 29, 2023
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Sponsor : Abiogen Pharma S.p.A
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Amgen Inc | EffRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2020
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Amgen Inc | EffRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Bisphosphonates for Prevention of Post-Denosumab Bone Loss
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2018
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Amgen Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2015
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Health Research Board, Ireland | Royal College of Surgeons, Ireland | Mater Misericordiae University Hospital | Beaumont Hospital | Rush University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 22, 2014
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Health Research Board, Ireland | Royal College of Surgeons, Ireland | Mater Misericordiae University Hospital | Beaumont Hospital | Rush University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : CIHR Canadian HIV Trials Network
Deal Size : Inapplicable
Deal Type : Inapplicable
Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2013
Lead Product(s) : Alendronate Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : CIHR Canadian HIV Trials Network
Deal Size : Inapplicable
Deal Type : Inapplicable